<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="668">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880412</url>
  </required_header>
  <id_info>
    <org_study_id>EHT0202/002</org_study_id>
    <nct_id>NCT00880412</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>EHT0202/002</acronym>
  <official_title>A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exonhit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exonhit</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this 3-month study is to assess the safety and efficacy of EHT 0202 in&#xD;
      addition to acetylcholinesterase inhibitor in patients suffering from Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this pilot study is to assess the safety and tolerability profile of 2 doses of&#xD;
      EHT 0202 (40 mg and 80 mg b.i.d) versus placebo in addition to a treatment with&#xD;
      acetylcholinesterase inhibitor and its exploratory efficacy on cognition, behavior,&#xD;
      activities of daily living, caregiver's burden and patient's global assessment, during a&#xD;
      3-month treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.</measure>
    <time_frame>all study visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognition (ADAS-Cog, Neuropsychological Test Battery, MMSE), patient's global functioning (CDR-SB,CGI), patient's behaviour (NPI), daily living activities (ADCS-ADL) and caregiver's burden. Population PK of EHT 0202 and PK/PD profile.</measure>
    <time_frame>at the end of the 3-month study treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>EHT 0202 40 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EHT 0202 80 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EHT 0202 etazolate</intervention_name>
    <description>In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.</description>
    <arm_group_label>EHT 0202 40 mg bid</arm_group_label>
    <arm_group_label>EHT 0202 80 mg bid</arm_group_label>
    <other_name>EHT 0202</other_name>
    <other_name>etazolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.</description>
    <arm_group_label>placebo bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory male or female patient, aged 60-90 years old included at screening, and&#xD;
             living at home.&#xD;
&#xD;
          -  Patient having a clinical diagnosis of probable AD according to National Institute of&#xD;
             Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related&#xD;
             Disorders Association (NINCDS-ADRDA) criteria.&#xD;
&#xD;
          -  Mild to moderate AD with a MMSE total score ≥ 12 and ≤ 24 at screening.&#xD;
&#xD;
          -  Written informed consent obtained from the patient or, if appropriate, from legal&#xD;
             representative according to local laws and regulations. The caregiver will also have&#xD;
             to sign a specific informed consent form regarding his/her participation in the study.&#xD;
&#xD;
          -  Patient treated for AD treatment with one AChEI (donepezil, galantamine, or&#xD;
             rivastigmine), according to the recommended posology mentioned in the summary of&#xD;
             product characteristics, for at least 3 months and with a stable dose for at least 2&#xD;
             months prior to screening. The dose should be kept unchanged throughout the study&#xD;
             duration.&#xD;
&#xD;
          -  Patient with a cerebral CT-scan or cerebral MRI compatible with AD diagnosis, with no&#xD;
             brain lesions that may be related to another diagnosis and that could be responsible&#xD;
             for the current patient's condition (ex, but not limited to, non-AD dementia, brain&#xD;
             injury, brain tumour, stroke, normal pressure hydrocephalus,…). A cerebral CT-scan or&#xD;
             cerebral MRI has to be performed and results have to be available prior patient's&#xD;
             randomization if the results of the brain imagery performed to settle the AD diagnosis&#xD;
             are not available in the patient's file. Brain imaging has also to be performed if&#xD;
             considered necessary by the investigator, such as in case of emerging neurological&#xD;
             symptoms or in case of worsening of existing neurological symptoms.&#xD;
&#xD;
          -  Neurological exam without any particularities or without any specific focal signs&#xD;
             likely to be related to other conditions than AD.&#xD;
&#xD;
          -  No contra-indication to AChEI treatment and absence of significant adverse events&#xD;
             considered to be related to AChEI treatment at screening and randomisation.&#xD;
&#xD;
          -  Patient and patient's caregiver able to comply with study procedures, notably&#xD;
             regarding the drug intake at the end of the meal which has to be supervised by the&#xD;
             caregiver or another competent person.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of vascular dementia according to NINDS-AIREN criteria, or other non-AD&#xD;
             dementia, or CNS pathology (including but not limited to brain injury, brain tumour,&#xD;
             stroke, normal pressure hydrocephalus, Parkinson's disease, epilepsy,multiple&#xD;
             sclerosis,…) that may be responsible for dementia.&#xD;
&#xD;
          -  Clinically significant pathology and/or uncontrolled condition, including but not&#xD;
             limited to cancer, infectious (like AIDS), gastro-intestinal, hepatic, renal,&#xD;
             respiratory, endocrine(like diabetes mellitus, thyroiditis) pathology.&#xD;
&#xD;
          -  History or current clinically significant psychiatric pathology (including but not&#xD;
             limited to psychotic disorders, bipolar disorder, personality disorders) that may&#xD;
             interfere with study assessments.&#xD;
&#xD;
          -  Current major depressive disorder, either treated or not, associated with clinically&#xD;
             significant symptoms.&#xD;
&#xD;
          -  Low blood level of vitamin B12, TSH levels out of normal range at screening.&#xD;
&#xD;
          -  Current forbidden medication intake or intake within 2 weeks prior to screening.&#xD;
&#xD;
          -  Recent history (within the past year prior to inclusion) or current cardiovascular&#xD;
             pathology and/or symptoms considered as clinically significant, including but not&#xD;
             limited to angina pectoris, uncontrolled arrhythmia, significant ECG abnormalities.&#xD;
             Lifetime history of heart failure, myocardial infarction, severe and/or uncontrolled&#xD;
             angina pectoris,and/or ventricular arrhythmia disqualifies the patient.&#xD;
&#xD;
          -  History or presence of clinically conditions that may interfere with product&#xD;
             metabolism or with study assessments.&#xD;
&#xD;
          -  Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg at&#xD;
             screening and/or randomisation.&#xD;
&#xD;
          -  QTc interval (Bazett's correction) ≥ 430 msec for male and ≥ 450 msec for female at&#xD;
             screening.&#xD;
&#xD;
          -  Laboratory values (biochemistry, haematology, urinalysis) considered as clinically&#xD;
             significant and/or that may interfere with study assessments, according to the&#xD;
             investigator.&#xD;
&#xD;
          -  ALAT, ASAT, ALP &gt; 2.5 times the upper normal limit (UNL), total bilirubin &gt; 1.5 UNL or&#xD;
             history of significant liver pathology including hepatitis caused by drugs, HBV, HCV.&#xD;
&#xD;
          -  BUN, creatinin &gt; 1.5 UNL.&#xD;
&#xD;
          -  Current or recent history of drug or alcohol abuse or dependence.&#xD;
&#xD;
          -  Patient not registered at &quot;Sécurité Sociale&quot;.&#xD;
&#xD;
          -  Participation in another study within 1 month prior to screening and during the whole&#xD;
             duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Vellas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Casselardit Hospital - University of Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Privé Les Magnolias</name>
      <address>
        <city>Ballainvilliers</city>
        <zip>91160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Bergerac</city>
        <zip>24100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fleyriat Hospital</name>
      <address>
        <city>Bourg en Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Foix Hospital</name>
      <address>
        <city>Ivry sur Seine</city>
        <zip>94026</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>La Seyne sur Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Salengro Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupuytren Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Léopold Bellan</name>
      <address>
        <city>Magnanville</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical 2</name>
      <address>
        <city>Montpellier</city>
        <zip>34080</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hôpital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical 2</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cochin Broca</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Rambouillet</city>
        <zip>78120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Rueil Malmaison</city>
        <zip>92500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purpan-Casselardit Hospital - University of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Bruno Vellas, MD</name_title>
    <organization>University of Toulouse - Purpan - Casselardit Hospital</organization>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>treatment</keyword>
  <keyword>phase II</keyword>
  <keyword>study</keyword>
  <keyword>cholinesterase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etazolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

